This article brief concerned with selective donor T-cell depletion (naïve) in allo-HCTs may be of broad interest to some.
May contribute to multi-modal reduction in SR-aGVHD mortality together with Ryoncil MSC type treatment. Good thing. Early days on this but of general interest re: strategic approaches to SR-aGVHD mitigation.
"...Recent T-cell separation techniques allowing for precision graft engineering by selectively eliminating aGVHD-causing T-cells (e.g. naïve T-cells) without loss of T-cells with beneficial functions and retaining and/or enriching immune regulatory populations (e.g. regulatory T-cells (Tregs) or myeloid-derived suppressor cells) have been tested and will continue to improve..." LINK
MSB Price at posting:
$2.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)